fig11

From: Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Figure 11. Drug prediction of MOMLS. (A) Pathways significantly activated in the high MOMLS score group as identified by the GSEA algorithm; (B) Predicted sensitivity of RRM1; (C-D) Correlation and differential analyses of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets; (E) Differential expression analysis of hub genes in normal vs. tumor tissues. MOMLS: Multi-omics-driven machine learning signature; GSEA: Gene Set Enrichment Analysis; RRM1: Ribonucleotide reductase M1; CTRP: Cancer Therapeutics Response Portal; PRISM: Profile Reporting Information System and Management; AUC: area under curve. ^*P < 0.05; ^**P < 0.01; ^***P<0.001; ^****P<0.0001.